Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

Human Vaccines

Volumn 7, Issue 7, 2011, Pages 768-775

  Moreira Jr , Edson D ^a   Palefsky, Joel M ^b   Giuliano, Anna R ^c   Goldstone, Stephen ^d   Aranda, Carlos ^e   Jessen, Heiko ^f   Hillman, Richard J ^g   Ferris, Daron ^h   Coutlee, Francois ⁱ   Vardas, Eftyhia ^j   Brooke Marshall, J ^k   Vuocolo, Scott ^k   Haupt, Richard M ^k   Guris, Dalya ^k   Garner, Elizabeth I O ^k  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^f J2: Private Clinic for Infectious Diseases   (Germany)

^g UNIVERSITY OF SYDNEY   (Australia)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j STELLENBOSCH UNIVERSITY   (South Africa)

^k MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Adolescent; Adult; Human papillomavirus (HPV); Male; Safety; Vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; APPENDICITIS; ARTICLE; CELLULITIS; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HETEROSEXUAL MALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFLUENZA; INJECTION SITE REACTION; INJURY; MAJOR CLINICAL STUDY; MALAISE; MALE; MALE HOMOSEXUAL; MORTALITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NONCARDIAC CHEST PAIN; PAPILLOMAVIRUS INFECTION; PEANUT ALLERGY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN DISEASE; SOFT TISSUE DISEASE; SORE THROAT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; WART VIRUS;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SAFETY; VACCINATION; YOUNG ADULT;

EID: 79960818080     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.7.15579     Document Type: Article

References (27)

1. World Health Organization. Human papillomavirus infection and cervical cancer. World Health Organization 2004. Available at: http://www.who.int/ vaccine-research/diseases/hpv/en/.
2. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002; 35:210-24.
3. Lu B, Wu Y, Nielson CM, Flores R, Abrahamsen M, Papenfuss M, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 2009; 199:362-71.
4. Aho M, Vesterinen E, Meyer B, Purola E, Paavonen J. Natural history of vaginal intraepithelial neoplasia. Cancer 1991; 68:195-7.
5. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31:14-9.
6. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006; 30:1513-8. (Pubitemid 44808787)
7. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006; 108:1361-8. (Pubitemid 44901008)
8. International Agency for Research on Cancer Working Group. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC. Lyon, France: IARC 2007:90.
9. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32:59-66.
10. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2006; 363:1488-9.
11. Giuliani L, Favalli C, Syrjanen K, Ciotti M. Human papillomavirus infections in lung cancer. Detection of E6 and E7 transcripts and review of the literature. Anticancer Res 2007; 27:2697-704. (Pubitemid 47227985)
12. Syrjänen KJ. HPV infections and oesophageal cancer. J Clin Pathol 2002; 55:721-8. (Pubitemid 35231898)
13. Giuliano AR, Lazcano E, Villa LL, Flores R, Salmeron J, Lee JH, et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer 2009; 124:1251-7.
14. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, et al. Age-specific prevalence, incidence and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827-35.
15. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, et al. Genital Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort of University Students. J Infect Dis 2007; 196:1128-36. (Pubitemid 47580267)
16. Outcomes following incident HPV 6/11/16/18 DNA detection in young men. Malmo, Sweden: 25th International Papillomavirus Conference 2009.
17. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43. (Pubitemid 46740303)
18. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
19. Barr E, Tamms G. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007; 45:609-17. (Pubitemid 47328643)
20. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Quadrivalent HPV vaccine efficacy against HPV infection and disease in men. New Engl J Med 2011; 364:401-11.
21. Merck & Co., Gardasil prescribing information. Merck, 2007. Available at: http://www.merck.com/ product/usa/pi-circulars/g/gardasil/gardasil-pi.pdf.
22. Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety and immunologic memory. Pediatrics 2001; 107:626-31. (Pubitemid 32268442)
23. Linglöf T, van Hattum J, Kaplan KM, Corrigan J, Duval I, Jensen E, et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability and immunogenicity. Vaccine 2001; 19:3968-71. (Pubitemid 32566321)
24. Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 2009; 373:1921-2.
25. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45. (Pubitemid 46393698)
26. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8. (Pubitemid 40590263)
27. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26. (Pubitemid 15055349)